Making More Efficient Use of Biospecimens. ISBER Contributions and Initiatives

Similar documents
IBBL BIOSERVICES BIOSPECIMEN PROFICIENCY TESTING

IBBL: Introduction to Biobanks and their services

WHITE PAPER FACTORS TO CONSIDER WHEN OUTSOURCING BIOREPOSITORY SERVICES

The Lifecycle of a Sample

Precision Biospecimen Solutions: Paving the Way to Personalized Medicine

IBBL BIOSERVICES SAMPLE ANALYSIS & QUALITY CONTROL

Correlative Science and Tissue Banking Procedures. Canadian Cancer Trials Group

Standards, Harmonisation and Audit. Anne Carter

A Gateway for Health: BBMRI and Africa Prof. Jan-Eric Litton Director General BBMRI-ERIC

Supplemental Table 1: an overview of technical guidelines for biospecimen handling guidelines available as Jan 1, 2010.

Asterand Bioscience Strategic Alliances

Sheng Lin-Gibson, Ph.D.

Economic Impact. IWGSC March 12, Jim Vaught, Ph.D. Jim Vaught, Ph.D. Deputy Director. ESBB Marseille November 2011

Audit & Restructure. Gastroenterology Cancer Resource Biorepository. Amanda Tanadinata May 19, 2016

SJÖGREN S INTERNATIONAL COLLABORATIVE CLINICAL ALLIANCE (SICCA) APPENDIX B: QUALITY ASSURANCE AND QUALITY CONTROL OF SPECIMENS

Cold Chain Planning for Clinical Studies of Regenerative Medicines

Dedicated to Molecular Diagnostics

PERSONALIZED CANCER CARE

ROUND TABLE ARISLA Milano 26 marzo 2014 Le BioBanche Nodo Italiano di Biobanking and Biomolecular Resources Research Infrastructure

Adapting research to the 21st century the Swedish Biobank Register

Interview. Maximizing the Value of Biospecimens to Deliver New Therapies. with Clive Green, PhD, Director and Head of Sample Management at AstraZeneca

Developing Common Biorepository Infrastructures

Arto Mannermaa. Research Manager, KUH Professor of personalized medicine and Biobanking, UEF

COPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES

This document is a preview generated by EVS

University of New Mexico Health Sciences Center Office of Research Policy for the Oversight of Human Tissue in Research

General Description of Codex4SMEs

Advancing utility and adoption of clinical genomic diagnostics

Lessons Learned: Challenges experienced by the NHLS/SU BIOBANK (NSB), a South African perspective

Each series will contain separately published parts under the generic specimen type according to specific methods.

The Hellenic Network of Biobanks-BBMRI-GR Dr. S.Kolyva Representative of Greece in the General Assembly of BBMRI-ERIC

Guide to Fulfillment of Validation and Verification of Examination Requirements

Scientific Basis for Selection of a Storage Temperature. Allison Hubel, PhD University of Minnesota

This document is a preview generated by EVS

NWIP on 'Molecular in-vitro diagnostic examinations - Specifications for pre-examination processes for blood - ccfdna'

FINAL DOCUMENT. Global Harmonization Task Force. Title: Clinical Evidence for IVD medical devices Key Definitions and Concepts

Sectioning of Paraffin and OCT Embedded Tissue. Signature

Transforming care for the future

Risk Mitigation in Breast Predictive Factor Testing. Elizabeth H Hammond MD

Controlling Preanalytical Variability in Biospecimen Collections

The Tissue Procurement Core (TPC) at the Washington

Monitoring Assay Traceability through EQAS Surveillance

Finnish Biobanks. The most advanced testbed in the world

IVD Regulation 2017/746

Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations

Optimising Clinical Laboratory Operations. Alan Brown SLAS Compound Management March 2017

Signature. This procedure applies to all biorepository personnel who are responsible for assessing the quality of nucleic acids.

US Policy Developments and Points to Consider for Genomics Research Informed Consent

EUROPEAN COMMISSION HEALTH & FOOD SAFETY. Directorate G Veterinary and International affairs. Unit G2- Animal health

From Liquid Biopsy to Result. Fully automated purification, reliable quantification and bisulfite conversion of cell-free circulating DNA

Discover the Importance of Third Party Quality Control

Short Title: CCI Biobank

SOLVING THE PATIENT RECRUITMENT DILEMMA

SALDA In Vitro Diagnostics in South Africa. Welcome. December 2015

BCNet Catalogue Dictionary_v1-1.xlsx 04/12/ :39

The EORTC Molecular Screening programme SPECTA

Perspective on Biorepository Return of Results and Incidental Findings

Preanalytical Variables in Blood Collection: Impact on Precision Medicine

Presented By: Rania Labib Head of Biorepository and Biospecimen Research Unit

Regulatory and Ethical Issues in Repository Research

FDA Regulation of Companion Diagnostics

ISO/IEC Conformity assessment General requirements for proficiency testing

Specialty Lab Services. Deep science at scale

NIA Aging Cell Repository Assurance Form for Cell Lines and DNA Samples

Global Biological Resource Leader

Developing an Individualized Quality Control Plan (IQCP) For Cepheid s GeneXpert Diagnostic Systems

Genomics and personalised medicine

From Liquid Biopsy and FFPE Samples to Results

ICH guideline E18 on genomic sampling and management of genomic data

Complete Success Begins with Sample Quality Control. Agilent 4150 and 4200 TapeStation Systems

CTRNet Standard Operating Procedure. Snap Freezing of Tissue

The Total Quality Management Program for HIV Clinical Trial Network Laboratories A Summary in Progress

Molecular Diagnostics

EU Big Data Initiatives

Consultation: Competence Standards for Medical Laboratory Science Practitioners in New Zealand

Specific Accreditation Criteria

Molecular Diagnostics Regulation Shifting from a Biomarker-Based Approach to an Algorithm-Based Approach

SOP# version e1.0 Material Handling and Documentation Preservation of Tissue: Paraffin Embedding

Verification or validation, that is the question

GMP. Safeguard The Patient s Health.

Le banche dei tessuti

BCNetter. Issue No. 5, September Message from the Editor. In this issue

MM12-A ISBN Volume 26 Number 20 ISSN Diagnostic Nucleic Acid Microarrays; Approved Guideline

Johns Hopkins Biological Repository

Ethics of Precision Medicine in Low to Middle Income Countries

From Liquid Biopsy and FFPE Samples to Results

GUIDELINE ON GENOMIC SAMPLING AND MANAGEMENT OF GENOMIC DATA E18

Project Proposal Form

Using Human Tissue in Translational Research and Clinical Trials

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL

The patient must address the treating physician directly if he/she has any questions or requires information regarding the test results.

ADAPTIVE BIOTECHNOLOGIES DIAGNOSTIC PORTAL: ACCOUNT LOGIN

NIGMS Human Genetic Cell Repository Material Transfer Agreement (Assurance Form) for Animal Cell Lines and DNA Samples

ISO INTERNATIONAL STANDARD

Next Generation Sequencing of HLA: Challenges and Opportunities in the era of Precision Medicine. Dr. Paul Keown, 2016

Customer Manual. General instructions for molecular diagnostic tests

The Intersection of Genomics Research and the IDE Regulation

Authorized, Uncontrolled Copy. Quality Manual

CADTH s Proposed Process for the Assessment of Companion Diagnostics

ISTA Tests for GMO seeds : New Rules Chapter and Handbook

Transcription:

Making More Efficient Use of Biospecimens. ISBER Contributions and Initiatives Members of the ISBER Education and Training Committee a,1, Members of the ISBER Science Policy a,1, Members of the ISBER Biospecimen Science Working Group a,1, Review prepared and presented by Fay Betsou a,b,1,2 a International Society for Biological and Environmental Biorepositories, b Integrated Biobank of Luxembourg Abstract. The International Society for Biological and Envirinmental Repositories (ISBER) is the leading global forum for promoting harmonized standards, ethical principles, and innovation in the science and management of biorepositories. Through development and publication of opinions and comments on ethical and legal issues underpinning the use of biospecimens in research, the ISBER Science Policy Committee supports biorepositories in all geographical regions, in order to ensure scientific use of biospecimens is possible, in accordance with applicable regulations and good ethical practice. In order for biopsecimens to be fit-for-purpose, the ISBER Education and Training Committee and the Biospecimen Science Working Group have developed Best Practices, educational programs and tools in order to support quality assurance in the daily operations of the biorepositories and in the characterization of biospecimens. Keywords. Biospecimen, ISBER, biorepository, biobank. Introduction ISBER is a global organization that creates opportunities for sharing ideas and innovations in biobanking and harmonizes approaches to evolving challenges for biological and environmental repositories. ISBER is a global scientific society, whose goal is to support biobanks worldwide. The mission of a biobank is to support research. In order for biobanks to fulfill this mission, ethical / legal and technical / scientific issues have to be dealt with, in an efficient way, in compliance with applicable regulations while taking into account the most recent scientific results. Efficient utilization of biospecimens requires that donors interests are respected, that biospecimens are not buried in biorepositories due to regulatory constraints, and that distribution takes place in time relative to their inherent stability. Efficiently utilized biospecimens are accurately identified and accompanied by relevant and verified data (taxonomical, clinical, pathological, epidemiological, pre-analytical). They have appropriate concentration, purity, integrity, and homogeneity for the end-uses and those that correspond to cases and controls are of comparable quality. Relevant ISBER Committees and Working Groups, composed of 1 Members of the 2014-15 Science Policy Committee, http://www.isber.org/?page=scipolcomm; members of Science Policy Committee before 2014, http://c.ymcdn.com/sites/www.isber.org/resource/resmgr/committee_rosters/2013science_policy_committee. pdf; members of the 2014-15 education and training Committee, http://www.isber.org/?etcommittee; members of the Education and training Committee before 2014, http://c.ymcdn.com/sites/www.isber.org/resource/resmgr/committee_ rosters/isber_education_and_training.pdf; members of the 2014-15 BSWG, http://www.isber.org/?page=bs; members of the BSWG before 2014, http://c.ymcdn.com/sites/www.isber.org/resource/resmgr/workinggroups/bswg-2008-2014_membership.pdf 2 Corresponding Author. 93

volunteer members from all over the world, have been actively developing documents and tools to ensure biospecimens can be used efficiently. 1. ISBER Science Policy Committee The Science Policy Committee includes members from the USA, South Korea, Italy, Luxembourg, Australia and New Zealand. The main objectives of the Committee are to communicate regarding emerging science policy issues that may affect the biorepository community. In this role, the committee also responds to requests for public comment on draft regulatory and policy documents. Members of the Committee have contributed to the ISBER Best Practices section on Legal and Ethical Issues for Biospecimens (informed consent, protection from research risks, specimens from mentally impaired, specimens from autopsies, pediatric specimens, communities, animal and wildlife biospecimens, sharing and distribution of specimens and data) and the section on Specimen Access, Utilization and Destruction (access and utilization, data sharing, benefit sharing, Material Transfer Agreements, data transfer). The ISBER Science Policy Committee has replied to the following requests for public comment: In 2011-2012, the Federal Government of the US Department of Health and Human Services proposed changes to the Common Rule. ISBER supported the use of left-over tissue without consent under appropriate circumstances with research oversight mechanisms and suggested that biospecimens should not be considered in and of themselves identifiable. ISBER fully endorsed the Australian Government National Health and Medical Research Council proposed revisions to Chapter 3.4: Human Tissue Samples and Chapter 3.6: Human Stem Cells of the National Statement on Ethical Conduct in Human Research. In 2013, in its Response to the European General Data Protection Regulation Proposal as provided by the European Parliament and the Council of the European Union, ISBER explained the possible impediment of some of the proposed provisions to the progress of global research, and supported the possibility of a waiver of consent under certain circumstances. In its response to the U.S. Presidential Commission for the Study of Bioethical Issues request for comments on issues related to incidental findings, ISBER suggested that instead of mandating return of incidental research findings to participants, that repositories should develop return of results policies that are reflected in the Informed Consent documents. In its response to the request for public comments on the Draft Genomic Data Sharing Policy, ISBER supported the need for data standards, the protection of indigenous populations, and the possibility of IRB approved waiver of consent under appropriate circumstances. In 2014, in its comments on the International Code of Conduct for genomic and healthrelated data sharing, ISBER suggested that the Code allow for waivers of informed consent for retrospective collections when approved by ethics review boards. 94 Biobanken-Forschung in Deutschland: Vom Konzept zur Realisierung

Finally, in its comments on the Working Document on Research on Biological Materials of Human Origin to the Committee on Bioethics of the Council of Europe, ISBER suggested a better definition of identifiable biospecimens, of future research, and supported the possibility of the use of broad consent, IRB/ethics committee board waiver of consent for persons not able to consent and storage of residual anonymized materials. ISBER suppor. ted the development of Biobank policies on individual feedback of results and raised the question of ownership of samples 2. ISBER Education and Training Committee The Education and Training Committee currently includes members from the US, Canada, Australia, Germany and South Africa. The main objective of the Committee is to identify ways to ensure that ISBER members have access to state-of-the-art information and tools to effectively establish and operate biorepositories, and preserve biospecimens for future research and analysis, following Best Practices. The ISBER Education and Training Committee has developed the following educational and training documents and tools: The ISBER Best Practices. This document contains a description of effective practices for the management of specimen collections and repositories. Adherence to ISBER Best Practices is strictly on a voluntary basis. The ISBER Best Practices are periodically reviewed and revised to reflect advances in research and technology. The third edition of the Best Practices was published in 2012. The Self Assessment Tool. This is a survey allowing participants to assess their degree of compliance with the ISBER Best Practices. It provides a risk-balanced score, based on a proprietary algorithm (developed by the ET Committee), which can be used as a quantitative quality indicator by those biobanks who decide to implement a quality management system. It supports continuous improvement and facilitates accountability to stakeholders. The Committee is currently working on additional educational resources and a Repository Technician Certificate program. 3. ISBER Biospecimen Science Working Group The ISBER Biospecimen Science Working Group (BSWG) currently includes members from the US, UK, Luxembourg, Italy, Switzerland, Australia, Canada, Belgium, Germany and Sweden. Biospecimens stored in biorepositories are intended to be used for biomarker identification and validation, among other things. The performance of such a biomarker greatly depends upon the pre-analytical variations of the samples utilized for its initial identification. Quality Assurance therefore is of utmost importance, making it possible to establish the right correspondence between processing methods and end-use biomarkers. The objectives of the ISBER BSWG include: selection of biospecimen quality assurance schemes identification of biospecimen handling critical points standardization of biospecimen research protocols identification of Quality Control tools 95

reviews on biospecimen science topics and validation of biospecimen processing and quality control methods. The ISBER BSWG has developed the following educational and quality assurance documents and tools: The Sample PREanalytical Code (SPREC), initially developed in 2009, has been successfully implemented in several biobanks by different ISBER members in the US, Europe and Australia. Two informatics tools have been developed which facilitate its further implementation. The first, developed by IBBL, is an excel calculator which automatically calculates the SPREC time-associated elements for solid and fluid samples. The second tool, developed by San Raffaele University Hospital, supports coding and decoding of a sample s SPREC, printing barcodes and storing the preanalytical data in a local database. The SPREC has spread beyond human biospecimens to the development of a SPREC paradigm for environmental biospecimens. SPREC version 2 was developed on the basis of feedback received from ISBER members who have implemented and utilized the SPREC since its first publication. The SPREC allows biorepositories to document the in vitro preanalytical history of biospecimens in a standardized way. Having established and updated a biospecimen science literature compilation, the BSWG readers did a critical review of more than 600 of these publications. The aim was to find biospecimen QC tools (markers or assays) that could be used to define sample quality. At present, there are few QC tools that are either predictive of downstream method feasibility and reliability, or diagnostic of upstream biospecimen processing steps. The most appropriate quality control tools, in terms of molecular diagnostic performance, and feasibility of application were selected by consensus. QC assays allow biorepositories to objectively assess the fitness for purpose of biospecimens. ISBER, together with the IBBL, has developed a biospecimen Proficiency Testing (PT) program for biorepositories, in compliance with ISO 17043. The PT program allows biobanks to assess the efficiency of their biospecimen processing methods, and the accuracy and precision of biospecimen QC methods. It supports biorepository accreditation initiatives, facilitates implementation of new QC tools and allows evaluation of their performance by comparing them to previously used QC methods. PT is another step towards standardized and accurately characterized biospecimens. The 2014 schemes include DNA extraction from whole blood, RNA extraction from whole blood, DNA extraction from FFPE cells, plasma metabolomics quality assessment, DNA quantification and purity, RNA integrity, cell viability and tissue histology. he BSWG also did some experimental work on RT RNA stability. Another experimental piece of work focused on the impact of shipping temperature and cryomedia on cell viability and functionality. The results were important for the RNA integrity and the cell viability PT schemes, mentioned above. Stability studies allow evidence-based biobanking. The Preanalytical External Quality Assurance (EQA) survey allows biorepositories to assess the quality assurance of their preanalytical phase (Fig. 1). In conclusion, ISBER s initiatives aim at facilitating research uses of biospecimens in ways that are legally possible and ethically sound, (Science Policy Committee), effectively orga- 96 Biobanken-Forschung in Deutschland: Vom Konzept zur Realisierung

nized (Education and Training Committee) and scientifically reliable (Biospecimen Science Working Group) (Fig. 2, Fig. 3). ISBER considers the above objectives as a manifestation of respect for both the environment and the human donors of specimens, by allowing researchers to make the best possible use of natural resources and clinical specimens. Figure 1. Example of Preanalytical EQA Survey Report. 97

Figure 2. The continuum of ISBER s contributions. Figure 3. The continuum of Quality Assurance tools developed by ISBER. Referenzen [1] The ISBER Working Group on Biospecimen Science. Human Biospecimen research: Experimental Protocol and Quality Control Tools. Cancer Epidemiol Biomarkers Prevention 2009; 18:1017-1025. [2] The ISBER Working Group on Biospecimen Science. Standard Preanalytical Coding for Biospecimens: Defining the Sample PREanalytical Code (SPREC). Cancer Epidemiol Biomarkers Prevention 2010; 19:1004-11. [3] ISBER Best Practices for Repositories: Collection, storage, retrieval and distribution of biological materials for research. Third Edition. Biopreservation and Biobanking 2012; 10:79-161. [4] Standard PREanalytical Codes (SPREC): A New Paradigm for Environmental Biobanking Sectors Explored in Algal Culture Collections. Biopreservation and Biobanking, 2011; 9:1-12. [5] Standard preanalytical coding for biospecimens: Review and implementation of the Sample PREanalytical Code (SPREC). Biopreservation and Biobanking 2012; 10:366-374. [6] Development of external quality assurance programs for biorepositories. Biopreservation and Biobanking, The ISBER Corner 2012; 10:403-404. [7] Short-term stability study of RNA at room temperature. Biopreservation and Biobanking 2012; 10:532-542. [8] The ISBER Best Practices Self Assessment Tool (SAT). Lessons learnt after three years of collecting responses. The ISBER Corner. Biopreservation and Biobanking 2012; 10:548-549. [9] Identification of evidence-based biospecimen quality control tools. J Mol Diagnostics 2013; 15:3-16. [10] The ISBER Proficiency Testing Program: two successful years already, and new features to come. Biopreservation and Biobanking; 2013; 11. [11] Viable mononuclear cell stability study for implementation in a proficiency testing program: impact of shipment conditions. Biopreservation and Biobanking 2014; 12:206-216. [12] http://c.ymcdn.com/sites/www.isber.org/resource/resmgr/isber-comments_on_proposed_c.pdf [13] http://c.ymcdn.com/sites/www.isber.org/resource/resmgr/isber-comments_on_nhrc_propo.pdf [14] http://c.ymcdn.com/sites/www.isber.org/resource/resmgr/isberspcresponsetoesbbprivac.pdf [15] http://c.ymcdn.com/sites/www.isber.org/resource/resmgr/documents/isber_presidential_commissio.pdf 98 Biobanken-Forschung in Deutschland: Vom Konzept zur Realisierung

[16] http://c.ymcdn.com/sites/www.isber.org/resource/resmgr/documents/isber_response_to_draft_nih_.pdf [17] http://c.ymcdn.com/sites/www.isber.org/resource/resmgr/files/isber_comments_on_code_of_co.pdf [18] http://c.ymcdn.com/sites/www.isber.org/resource/resmgr/documents/isber_comments_on_dh-bio_wor.pdf [19] http://www.isber.org/?page=ptgi [20] http://www.isber.org/?page=sat [21] http://www.isber.org/?page=eqasurvey [22] http://www.isber.org/?page=sprec [23] http://c.ymcdn.com/sites/www.isber.org/resource/collection/b1088675-1b3c-414c-b280-fb84327d3675/ ISBER_BIOSPECIMEN_SCIENCE_LITERATURE_COMPILATION.pdf 99